Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 29;295(29):9934–9947. doi: 10.1074/jbc.RA120.014587

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Das et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Figure 7. — Ap5A showed comparable antileishmanial efficacy with AmB. A, E, F, and H, the viability of axenic promastigotes (A and F) and healthy BMDMs (E and H) treated with Ap5A and AmB was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction assay. B, pH sensitivity and temperature sensitivity of Ap5A (15 μm)-treated WT and LdHSP78+/−promastigotes were compared by determination of promastigote growth. C and G, Giemsa staining was performed to calculate the amastigote burden of BMDMs, infected with L. donovani for 24 h and treated with either Ap5A or AmB. A and D, the comparative sensitivity of WT, LdHSP78+/−, and resKO promastigotes and amastigotes for Ap5A treatment was analyzed to understand the specificity of Ap5A for LdHSP78. Each experimental set is representative of three samples, and error bars are mean ± S.D. Statistical significance was analyzed using one-way analysis of variance followed by Dunnett's multiple-comparison test.